Citation

Visentin P, Ciravegna R, Fabris F. Maturitas 1997; 26(3): 185-192.

Affiliation

Department of Gerontology, University of Turin, San Giovanni Battista Hospital, Torino, Italy.

Copyright

(Copyright © 1997, Elsevier Publishing)

DOI

unavailable

PMID

9147350

Abstract

OBJECTIVES: A cost-effectiveness analysis on osteoporosis treatment has been carried out as the basis for an estimate of the cost per avoided hip fracture (CPAHF) in Italy. METHODS: We have assumed as correct, reported data on the efficacy of calcitonin in preventing hip fractures in European women over 50 (Mediterranean Osteoporosis Study). Health-care costs were calculated using Weinstein and Stason's equation. RESULTS: Given the incidence of such fractures in Italy and their cost to the health service, we calculate that in order to prevent one hip fracture 1285 women need to be treated with calcitonin at a cost of over two million dollars. The introduction of an element of screening (bone mass measurement to select a high risk subpopulation) would reduce the CPAHF by 65%. Choice of a more effective treatment (as the hormone replacement therapy) would be cost-neutral. CONCLUSIONS: Drug-related costs, selection of high risk subpopulations and drug efficacy have important implications in the estimation of optimal CPAHF.

Language: en